Clinical efficacy of combined propranolol and imiquimod treatment in infantile hemangioma of proliferative phase
10.3760/cma.j.issn.1671-0290.2016.02.011
- VernacularTitle:普萘洛尔联合咪喹莫特治疗增生期婴幼儿血管瘤的临床效果
- Author:
Jie ZHANG
;
Jian MENG
;
Zhiping LI
- Publication Type:Journal Article
- Keywords:
Propranolol;
Imiquimod;
Infantile;
Hemangioma
- From:
Chinese Journal of Medical Aesthetics and Cosmetology
2016;22(2):98-101
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical effect and safety of propranololand imiquimod therapy for infantile hemangiomas of proliferative phase.Methods A total of 53 infantile patients with hemangiomas of proliferative phase that were treated in our department were collected.According to patient's condition,the patients were classified into treatment group and observation group.The treatment group consisted of 34 patients received propranolol and imiquimod treatment,and 19 cases belonged to the observation group.The changes of tumor were compared between the treatment group and the observation group.Pre-therapeutic and post-therapeutic heart rate,blood pressure,blood glucose were monitored in the treatment group,so were in post-treatment.Results After 6 months,the effective rate was 97.1％ (33/34) in treatment group,and the effective rate was 57.9％ (11/19)in observation group.There was significant difference between treatment group and observation group in effective rate (P＜0.05),and so did blood pressure and heart rate after medication in the treatment group,but not in blood glucose,heart rate six hours after medication (P＞0.05).Conclusions Propranolol and imiquimod therapy has a certain inhibitory effect on infantile hemangiomas of proliferative phase.Propranolol and imiquimod are safe in patients with infantile hemangioma,and adverse reactions are mild.
